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Abstract
Background: The suppression of amber stop codons with non-canonical amino acids (ncAAs) is used for the site-specific
introduction of many unusual functions into proteins. Specific orthogonal aminoacyl-tRNA synthetase (o-aaRS)/amber
suppressor tRNACUA pairs (o-pairs) for the incorporation of ncAAs in S. cerevisiae were previously selected from an E. coli
tyrosyl-tRNA synthetase/tRNACUA mutant library. Incorporation fidelity relies on the specificity of the o-aaRSs for their ncAAs
and the ability to effectively discriminate against their natural substrate Tyr or any other canonical amino acid.
Methodology/Principal Findings: We used o-pairs previously developed for ncAAs carrying reactive alkyne-, azido-, or
photocrosslinker side chains to suppress an amber mutant of human superoxide dismutase 1 in S. cerevisiae. We found
worse incorporation efficiencies of the alkyne- and the photocrosslinker ncAAs than reported earlier. In our hands, amber
suppression with the ncAA containing the azido group did not occur at all. In addition to the incorporation experiments in
S. cerevisiae, we analyzed the catalytic properties of the o-aaRSs in vitro. Surprisingly, all o-aaRSs showed much higher
preference for their natural substrate Tyr than for any of the tested ncAAs. While it is unclear why efficiently recognized Tyr
is not inserted at amber codons, we speculate that metabolically inert ncAAs accumulate in the cell, and for this reason they
are incorporated despite being weak substrates for the o-aaRSs.
Conclusions/Significance: O-pairs have been developed for a whole plethora of ncAAs. However, a systematic and detailed
analysis of their catalytic properties is still missing. Our study provides a comprehensive scrutiny of o-pairs developed for the
site-specific incorporation of reactive ncAAs in S. cerevisiae. It suggests that future development of o-pairs as efficient
biotechnological tools will greatly benefit from sound characterization in vivo and in vitro in parallel to monitoring
intracellular ncAA levels.
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Introduction
Protein engineering with non-canonical amino acids (ncAAs)
that are not encoded by the standard genetic code has gained
much attention in the recent years. The approach is particularly
interesting because it provides for the introduction of unusual
functions into target proteins directly by ribosomal translation.
Especially the incorporation of amino acid analogs bearing azide
or alkyne side chains for subsequent bioorthogonal copper(I)-
catalyzed [3+2]-cycloaddition [1] with alkyne-, or azido-ligands,
respectively, is a valuable technique for the artificial post-
translational modification of proteins. We and others have
successfully used the methionine analogs azidohomoalanine,
azidonorleucine, and homopropargylglycine [2,3,4] for the global
substitution of Met residues in target proteins and subsequent
orthogonal conjugation with fluorescent dyes, biotin, sugars, or
PEG [5,6,7,8,9,10,11]. Quasi site-specific incorporation and
conjugation, however, is only possible if the target protein contains
a single Met.
Genuine site-specific incorporation of ncAAs is feasible at in-
frame stop codons. Furter first demonstrated the introduction of p-
fluoro-L-phenylalanine (pFF) at an amber stop codon in vivo by a
‘‘nonessential heterologous tRNA/synthetase pair’’ [12]. To
specifically decode the amber stop codon with pFF, he chose the
yeast phenylalanyl-tRNA synthetase (yPheRS) that is specific for
Phe yet naturally tolerates pFF as a substrate. He introduced the
yPheRStogetherwitha compatible ambersuppressortRNACUA
Phe
into a Phe-auxotrophic E. coli strain harboring an endogenous
PheRS mutant with greatly reduced affinity for pFF [12].
Since the identity elements of PheRS/tRNA
Phe pairs differ in S.
cerevisiae and E. coli [13], there is little cross-species aminoacylation,
i.e., the pairs are orthogonal. However, the yPheRS did not have
exclusive substrate specificity for pFF, therefore, the Phe-auxotro-
phy of the host was required to perform the incorporation in the
presence of low amounts of Phe and excess pFF. This approach
ensured that Phe was still incorporated at Phe codons while
predominantly pFF appeared at the position of the amber stop
codon.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e31992Schultz and co-workers further developed the concept of
orthogonal aminoacyl-tRNA synthetase/suppressor tRNACUA
pairs (o-pairs) and devised an efficient screening system for the
selection of orthogonal mutant aaRSs (o-aaRSs) with novel
specificities for ncAAs [14,15]. The orthogonality is achieved by
importing aaRSs together with appropriate suppressor tRNAs
from distantly related organisms into the host, e.g., E. coli
components in yeast. O-pairs are paramount with respect to site
specificity as they allow the incorporation of an ncAA exactly at
the position of an in-frame amber stop codon. During the last
decade, the Schultz group and others established o-pairs for the
incorporation of a vast number of mostly Tyr analogs in different
expression hosts [16,17,18,19,20,21,22,23]. Tyr analogs with
reactive side chains, such as p-azido-L-phenylalanine (AzF), or p-
propargyloxy-L-phenylalanine (PxF; Figure 1) were successfully
incorporated into target proteins at amber codons and used for
bioorthogonal conjugation. Recently, a new generation of o-pairs
has been developed that derive from naturally occurring pyrrolysl-
tRNA synthetase (PylRS)/tRNACUA pairs from methanogenic
archaea and allow the incorporation of lysine analogs at in-frame
amber codons (see [15] and references therein).
As outlined above, Furter used a Phe-specific orthogonal
yPheRS with a natural tolerance for pFF as the substrate, in
combination with a host PheRS mutant that was inefficient for
pFF recognition. The Schultz approach, however, employs ncAA-
specific o-aaRSs derived from tyrosyl-tRNA synthetase (TyrRS),
or PylRS by directed evolution of specific amino acid residues in
the substrate binding pocket [17,18,24]. As such, the o-aaRS/
tRNACUA pairs represent autonomous decoding units for amber
stop codons with a particular ncAA, that neither cross-react with
host tRNAs, nor with host aaRSs. The fidelity of the system relies
on the inability of the o-aaRS to charge its cognate tRNACUA with
the natural substrate, Tyr, or any other of the canonical amino
acids.
Despite the vast number of o-pairs that have been described so
far, a systematic analysis of their catalytic properties has not yet
been performed. In order to curtail this evidence gap we decided
to perform a comprehensive characterization of o-pairs for the
incorporation of ncAAs with reactive side chains at amber codons
in yeast. The yeast S. cerevisiae is superior to bacterial expression
hosts such as E. coli for the expression of integral membrane
proteins and protein complexes, or for protein secretion [25,26].
Using appropriate AzRS/tRNACUA or PxRS/tRNACUA pairs we
intended to functionalize a target protein in the yeast with reactive
handles by incorporation of AzF or PxF, respectively. We also
included the o-pair for the photocrosslinker, p-benzoyl-L-phenyl-
alanine (Bpa; Figure 1) in our study. The expansion of the genetic
code with these Tyr analogs in yeast has attracted much attention
[18], however, we obtained only minute amounts of target protein
labeled with PxF and Bpa while AzF was not incorporated at all.
In order to systematically analyze the reason for the poor
incorporation, we expressed the corresponding o-aaRSs in E. coli,
purified them to homogeneity and analyzed their catalytic
activities. We found that under our assay conditions, none of the
ncAAs was demonstrably activated while Tyr was recognized by
all of them. We speculate that ncAAs that are poor substrates for
the o-aaRSs can still be incorporated at amber codons if they
accumulate in the cell due to metabolic inertness.
Results
Incorporation of tyrosine analogs into an amber mutant
of hSOD1 in S. cerevisiae
For our performance analysis of o-pairs in yeast, we first
intended to reproduce the site-specific introduction of azido or
alkyne groups into a target protein in S. cerevisiae as described
earlier [18]. To achieve this, we reconstructed the expression
vectors pAz1/tRNACUA and pAz6/tRNACUA (Figure S1) for
incorporation of AzF and PxF (Figure 1), respectively, as described
in the relevant literature [18,19,27,28]. Though carefully recon-
structed, our expression constructs might nevertheless have
deviated from the original vectors in some unrecognized aspect.
Thus, we expanded our o-pair vector collection with the original
plasmids pAz3/3SUP-tRNACUA [29] and pPR1/3SUP-tRNACUA
[29], which were a kind gift by P.G. Schultz . The o-pair for the
photo-crosslinker Bpa (Figure 1) had been applied successfully in
yeast [18,29,30,31,32]. For this reason, we used pBpa/tRNACUA
[18] (kindly provided by S. Hahn and P.G. Schultz) as a positive
control together with pTyr/tRNACUA (reconstructed according to
[27]). A schematic map of the expression plasmids for the o-pairs
Figure 1. Structures of tyrosine and its analogs used in this study. Structures, names and abbreviations are shown.
doi:10.1371/journal.pone.0031992.g001
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S2 shows a sequence comparison of the different o-aaRSs.
Upon incorporation of AzF into their target protein, Chin et al.
observed the reduced form, p-amino-L-phenylalanine (AmF;
Figure 1) by tandem mass spectrometry [18] rather than AzF.
This observation was attributed to the chemical reactivity and
photoinstability of the azido group during mass analysis [21].
However, S. cerevisiae can be used as a biocatalyst to reduce
arylazides to arylamines [33,34]. Therefore, we included AmF in
our systematic studies in order to analyze whether AzRS would
use AmF as a substrate.
In accordance with reports from the Schultz lab, we chose the
human superoxide dismutase (hSOD1) as the target protein for
analog incorporation. hSOD1 is a small, stable protein [35] that is
well expressed in yeast. We first tested the expression efficiency of
wild type hSOD1 from a construct similar to that of the Schultz
group [18]. However, the expression of hSOD1 carrying a C-
terminal hexahistidine-tag from the high copy, galactose inducible
yeast-E. coli shuttle vector pYES2 was low and we did not obtain
pure protein preparations (data not shown). For that reason, we
replaced the hexahistidine-tag, which has been described as not
ideally suitable for yeast [36], with a Strep-tag II. In addition, we
exchanged the inducible GAL1 promoter for the strong constitutive
PGK1 promoter. The strength of this promoter is comparable to
that of the TDH3 promoter [26], which Chen et al. used for
hSOD1 expression together with an improved orthogonal system
for tyrosine analogs in yeast [29]. Using this modified expression
construct, we obtained pure hSOD1 in high yield (unpublished
observation). For the incorporation of the amino acids shown in
Figure 1, we introduced a Trp (TGG) to amber stop codon (TAG)
mutation into hSOD1 at position 33. Previous reports demon-
strated the permissiveness of this position for analog incorporation
by amber suppression [18,37,38,39,40]. The map of the resulting
expression construct, as well as the coding DNA sequence and the
protein sequence of hSOD1(W33TAG) with a C-terminal Strep-tag
II are shown in Figure S3 and Figure S4 of the supporting
information.
Similar to the original study [18], we performed all Tyr analog
incorporations in the Saccharomyces cerevisiae strain InvSC1 (see
Materials and Methods for experimental details). Each of the o-
pairs listed in Table 1 was introduced into InvSC1 together with
the hSOD1(W33TAG) expression construct. We examined the
efficiency of the amber suppression in hSOD1(W33TAG) using
the wild type E. coli TyrRS/tRNACUA o-pair with Tyr. In order to
scrutinize a potential residual affinity of AzRS3 for the natural
substrate Tyr, we used Tyr together with the AzRS3/3SUP-
tRNACUA pair. For comparison of the incorporation efficiencies,
hSOD1(W33TAG) was expressed in the presence of AzF and
three o-pairs with corresponding substrate specificity, AzRS1/
tRNACUA, AzRS6/tRNACUA, or AzRS3/3SUP-tRNACUA. The
same o-pairs were also used with AmF. In addition, we wanted to
introduce PxF into hSOD1(W33TAG) by the AzRS6/tRNACUA
[18], or PxRS/tRNACUA [29] o-pairs. Finally, we introduced Bpa
into hSOD1(W33TAG) with the corresponding BpaRS/tRNA-
CUA o-pair.
Full-length hSOD1(W33X) variants, where X denotes Tyr or an
ncAA, are expressed only if the in frame amber stop codon at
position 33 is efficiently suppressed by Tyr or one of its analogs
shown in Figure 1. In contrast to E. coli, expression of heterologous
proteins in S. cerevisiae is very often too low for detection on SDS
gels in spite of the use of high copy expression vectors. Usually, the
foreign protein can be immunodetected in whole cell lysates using
suitable antibodies. However, we were unable to detect the full-
length hSOD1(W33X) variants in whole cell lysates by immuno-
blotting with an anti-Strep-tag II antibody. We observed specific
bands on the immunoblot (Figure 2) only after purification and
concentration of the tagged hSOD1 variants.
We detected an hSOD1 signal on the immunoblot upon
expression in the presence of the orthogonal TyrRS/tRNACUA
pair together with Tyr, indicating successful amber stop codon
suppression (Figure 2A and 2B, lanes 1). AzRS3/3SUP-tRNACUA
in combination with Tyr caused barely detectable expression of
full-length hSOD1 (Figure 2B, lane 3), which suggests good fidelity
of this o-pair. However, all our attempts to incorporate AzF into
hSOD1(W33TAG) with any of the o-pairs involving AzRS failed
(AzRS1/tRNACUA, Figure 2A, lane 2; AzRS3/3SUP-tRNACUA,
Figure 2B, lane 2; AzRS6/tRNACUA, Figure 2A, lane 4).
Surprisingly, we observed strong signals on the immunoblot in
two of three hSOD1(W33TAG) expressions with the AzRS3/
3SUP-tRNACUA pair and AmF (Figure 2B, lanes 4–5). The third
replicate yielded only a faint band (Figure 2B, lane 6) while no
bands were detected with AmF and the o-pairs involving AzRS1
and AzRS6 (Figure 2A, lanes 3 and 6). Contrary to the original
study, in which a dual specificity of AzRS6 for AzF and PxF was
reported [19], we obtained an hSOD1 signal on the immunoblot
only when PxF was used together with PxRS1 (Figure 2A, lane 7),
and not with AzRS6 (Figure 2A, lane 5). This observation may be
attributed to the improved expression of the suppressor tRNA
from the pPR1/3SUP-tRNACUA vector. In this construct, the
suppressor tRNA is inserted between short upstream and
downstream regions of the yeast SUP4 gene. Three copies of this
cassette are expressed in tandem from the strong PGK1 promoter
Table 1. Details of the orthogonal pairs used for the in vivo incorporation of Tyr analogs into hSOD1(W33TAG).
Orthogonal pair aaRS Specificity 6xHis-tag on aaRS tRNACUA copy number tRNACUA promoter Source
TyrRS/tRNACUA TyrRS Tyr none 1 internal B-box reconstructed from [18]
AzRS1/tRNACUA AzRS1 AzF none 1 internal B-box reconstructed from [18]
AzRS3/3SUP-tRNACUA AzRS3 AzF C-term. 3 improved* [29]
AzRS6/tRNACUA AzRS6 AzF [18], PxF [19] none 1 internal B-box reconstructed from [18,19]
PxRS1/3SUP-tRNACUA PxRS1 PxF C-term. 3 improved* [29]
BpaRS/tRNACUA BpaRS Bpa none 1 internal B-box [18]
The pairs consist of E. coli TyrRS, or a mutant descendant, and E. coli amber suppressor tRNACUA. The aaRSs are expressed under the strong, constitutive ADH1 promoter
(refer to Figure S1 for plasmid map details).
*The improved promoter consists of a yeast PGK1 promoter followed by three copies of the E. coli tRNACUA gene (with an internal B-box), each flanked by 55 bp
upstream and 30 bp downstream sequences of the yeast SUP4 gene [29].
doi:10.1371/journal.pone.0031992.t001
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the pAz3/3SUP-tRNACUA vector, which might explain the strong
expression of hSOD1 in the presence of AmF with AzRS3 but not
with AzRS1 or AzRS6. O-pairs with the latter aminoacyl-tRNA
synthetases contain only a single copy of tRNACUA (Table 1).
As expected, we observed a clear signal for hSOD1 expression
in the presence of Bpa and the BpaRS/tRNACUA o-pair
(Figure 2C, lane 1).
All hSOD1 variants were purified as described in the Methods
section and further analyzed by LC-ESI-MS (Figure 3), regardless
whether they yielded signals on the immunoblot or not. The found
mass of the tyrosine variant matched an hSOD1(W33Y) protein in
which the N-terminal Met had been excised and the second amino
acid, Ala, was acetylated (Table 2). Our observation is consistent
withpublished post-translational modificationsof hSOD1 produced
in S. cerevisiae [41]. Accordingly, these post-translational modifica-
tions were taken into account for the calculation of the variant
protein masses. In addition to hSOD1(W33Y), the formation of
hSOD1(W33PxF) and hSOD1(W33Bpa) was unambiguously
confirmed (Table 2). Although we had not detected a clear band
with the AzRS3/3SUP-tRNACUA pair and Tyr on the immunoblot
(Figure 2B, lane 3), the mass analysis confirmed the presence of
hSOD1(W33Y) also in this sample (Table 2). However, whether
AmF or rather Tyr (mass difference 1 Da) had been incorporated
into hSOD1(W33TAG) using the AzRS3/3SUP-tRNACUA pair in
combination with AmF could not be unambiguously deduced from
our mass analyses due to low resolution (Figure 3D–F). The mass
spectra of hSOD1 preparations with AzF showed only background
noise signal (data not shown).
The yields of the confirmed hSOD1(W33X) variants (Table 2)
ranged between approximately 42 and 120 mg per liter yeast
culture. These amounts are noticeably lower than the previously
published values of milligrams per liter culture [29,42]. The
protein concentrations of the variant preparations were too low to
allow analysis of their purity by SDS-PAGE.
Due to the inefficient or inexistent incorporation of PxF and
AzF, respectively, we analyzed the intracellular expression of their
specific aaRSs by immunoblotting. The expression of AzRS1 from
pAz1/tRNACUA was clearly visible, however, we could hardly
detect AzRS3 and PxRS (Figure S5).
In summary, we observed suppression of the amber stop codon
and hence expression of full-length hSOD1(W33X) with Tyr, Bpa,
PxF, and AmF but not with AzF. The incorporation of Tyr, Bpa,
and PxF into the target protein was confirmed by ESI-MS analysis.
The incorporation of AmF could not be unambiguously revealed.
PxFwasonlyincorporatedinto the targetproteinwiththeimproved
PxRS1/3SUP-tRNACUA o-pair (Table 1). In our hands, the o-pairs
for yeast performed less efficiently than expected although we
exactlyfollowedthepublished methodsandused originalexpression
constructs or reconstructed them according to previous reports.
In vitro activation of tyrosine analogs by the different o-
aaRSs
Besides the in vivo performance analysis, another important aim
of our study was to scrutinize the amino acid activation profiles of
the o-aaRSs in vitro. These data provide important information
about the substrate binding by the o-aaRSs. We performed in vitro
ATP-PPi exchange assays [43,44] (see Materials and Methods for
technical details) with the same o-aaRSs we had used for the in vivo
incorporation of Tyr analogs into hSOD1(W33TAG). Basically,
aminoacylation is indispensable for protein translation and occurs
in a two-step process. The amino acid is first activated and then
charged onto its cognate tRNA by a specific aaRS. The activation
reaction consumes ATP and pyrophosphate is released. As this
reaction is reversible, the amount of radioactive ATP that is
formed from [
32P]-pyrophosphate in the reverse reaction is a
measure for the activation of an amino acid by an aaRS.
In order to prepare pure enzymes for the activation assay, we
constructed His-tagged fusions of TyrRS, AzRS1, AzRS6, AzRS3,
and BpaRS for expression in E. coli and subsequent purification by
Ni-chelate chromatography (refer to Materials and Methods for
details). The purified aaRSs were characterized by SDS-PAGE
(Figure S6) and ESI-MS analysis (Table S1; Figure S7). In a first
step we determined the optimal amino acid concentration range
for the assay. To achieve this, we quantified the radioactive ATP
produced by 1 mM TyrRS within 15 minutes with a range of Tyr
concentrations (Figure S8). A steady increase in ATP formation
and hence amino acid activation was found for Tyr concentrations
between 5 mM and 100 mM. Tyr concentrations above 100 mM
saturated the enzyme and did not further increase ATP formation.
Figure 2. In vivo incorporation of Tyr and its analogs by amber suppression. hSOD1(W33TAG) was expressed in the presence of an o-pair
and one of the analogs shown in Figure 1 as indicated below. The variant proteins were immunodetected using a monoclonal anti-Strep-tag II
antibody (refer to the Materials and Methods section for experimental details). The average calculated molecular weight of hSOD1(W33X) is 17 kDa.
(A) 1, TyrRS/tRNACUA + Tyr (replicate 1); 2, AzRS1/tRNACUA + AzF; 3, AzRS1/tRNACUA + AmF; 4, AzRS6/tRNACUA + AzF; 5, AzRS6/tRNACUA + PxF; 6, AzRS6/
tRNACUA + AmF; 7, PxRS1/3SUP-tRNACUA + PxF; M; molecular weight marker; +, wild type hSOD1 with a C-terminal Strep-tag II. (B) 1, TyrRS/tRNACUA +
Tyr (replicate 2); 2, AzRS3/3SUP-tRNACUA + AzF; 3, AzRS3/3SUP-tRNACUA + Tyr; 4, AzRS3/3SUP-tRNACUA + AmF (replicate 1); 5, AzRS3/3SUP-tRNACUA +
AmF (replicate 2); 6, AzRS3/3SUP-tRNACUA + AmF (replicate 3); M and + as indicated in (A); -, empty lane. (C) 1, BpaRS/tRNACUA + Bpa; M and + as
indicated in (A).
doi:10.1371/journal.pone.0031992.g002
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AmF by TyrRS and the ncAA-specific AzRS1, AzRS3, AzRS6,
and BpaRS (Figure 4 and Figure 5). With the latter enzyme, an
activation assay with Bpa was also performed. We suspected the
Tyr analogs to be worse substrates for their cognate aaRSs than
Tyr is for the TyrRS. Therefore, the amino acids were added in
excess to a final concentration of 5 mM each. 1 mM TyrRS, 5 mM
of the AzRS proteins, and 3 mM BpaRS were used in the assay.
Tyr and its analogs are barely water soluble, thus, the substances
were dissolved in 0.01 M HCl. Accordingly, the negative control
(Figure 4 and Figure 5; w/o aa) contained no amino acid but the
appropriate amount of HCl.
As expected, Tyr was efficiently activated by TyrRS (Figure 4A).
The activation data are in good agreement with the successful
incorporation of Tyr in vivo (Figure 2A and 2B, lanes 1). TyrRS did
not activate AzF nor AmF (Figure 4A), confirming the lack of
natural tolerance for these substrates. However, we found no
activation either of AzF or AmF by AzRS1, AzRS3, or AzRS6
(Figure 4B–D). On the contrary, all AzRSs activated Tyr
(Figure 4B–D). Similarly, BpaRS did not activate Bpa but Tyr
was efficiently recognized (Figure 5). The inactivity of AzF in the
ATP-PPi exchange assay with the AzRSs coincides with our
finding that this analog was not incorporated into hSOD1(W33-
TAG) in vivo (Figure 2). In contrast, hSOD1 was expressed in the
presence of AmF (Figure 2B, lanes 4–6) and Bpa (Figure 2C, lane
1), yet the analogs were not activated in vitro.
In order to exclude that the high concentration (5 mM) of the
Tyr analogs caused an inhibition of the o-aaRSs, we assayed the
activation of Tyr, AzF, and AmF also in the lower concentration
range (500, 50, 5, and 1 mM; Figure S9). Once again, Tyr was
activated in a concentration dependent manner while we did not
detect activation of AzF nor of AmF.
In summary, under our experimental conditions the o-aaRSs
did not demonstrably activate the Tyr analogs but properly
activated their original substrate, Tyr.
Discussion
We evaluated the incorporation of reactive ncAAs with existing
o-pairs at the in-frame amber codon of an hSOD1(W33TAG)
mutant in yeast. AzF-, PxF-, and Bpa-specific o-aaRSs for the
corresponding o-pairs in S. cerevisiae were first evolved by Chin et al.
[18]. The same o-aaRSs were used later to construct an improved
expression system in yeast [29], and to establish the amber
suppression incorporation of these ncAAs in P. pastoris [20].
The Schultz group reported incorporation of AzF and PxF into
hSOD1 in yeast using the evolved o-pairs [18] and subsequent
bioorthogonal conjugation to alkyne- or azido-functionalized
fluorophores [19] and PEG [42]. Becker et al. used the Bpa-
specific o-pair to introduce Bpa site-specifically into the G-protein
coupled receptor (GPCR) Ste2p in yeast. The Bpa-labeled Ste2p
could then be photocrosslinked to its peptide ligand [31]. The
groups of Sakmar and Wang used the AzF- and Bpa-specific o-
pairs developed in yeast to incorporate these ncAAs into proteins
expressed in mammalian cells [45,46]. Different GPCRs were
labeled with AzF and Bpa for subsequent dynamics measurements
by Fourier-transform infrared (FTIR) difference spectroscopy
[47,48] and to analyze ligand binding [49,50] (for a comprehen-
sive review on the incorporation of molecular probes to study
GPCRs see [51]).
Although we used original or thoroughly reconstructed tandem
expression constructs for the o-pairs and followed published
methods, we obtained unexpected results. In our hands, none of
the three different AzRS/tRNACUA pairs (Table 1) previously
described to work efficiently [18,19,29,42] promoted amber
suppression with AzF.
PxF and Bpa were incorporated by their cognate o-pairs in
response to the amber codon at position 33 of hSOD1, though less
efficiently (Table 2) than previously reported [29]. This finding
indicates that the failure to incorporate AzF with the AzRS/
tRNACUA o-pairs did not originate from our experimental setup.
Figure 3. ESI-MS analyses of hSOD1 variants detected on the immunoblot in Figure 2. The o-aaRS which was used for amino acid
incorporation is given in brackets. hSOD1(W33Y) (TyrRS), replicate 1 (A); hSOD1(W33Y) (TyrRS), replicate 2 (B); hSOD1(W33Y) (AzRS3) (C);
hSOD1(W33AmF) (AzRS3), replicate 1 (D); hSOD1(W33AmF) (AzRS3), replicate 2 (E); hSOD1(W33AmF) (AzRS3), replicate 3 (F); hSOD1(W33PxF) (PxRS1)
(G); hSOD1(W33Bpa) (BpaRS1) (H). For the interpretation of the main peaks (bold mass labels) refer to Table 2; none of the minor peaks (standard
mass labels) corresponds to the calculated mass of hSOD1 variants containing either a canonical amino acid at position 33 or an ncAA shown in
Figure 1 (analysis details not shown).
doi:10.1371/journal.pone.0031992.g003
Table 2. ESI-MS analyses of selected hSOD1 variants.
Analog Orthogonal pair Calculated mass (Da)
1 Detected mass (Da) Dm (Da) Interpretation Protein per liter culture
Tyr replicate 1 TyrRS/tRNACUA 17021.6943 17043.0495 21.355 +Na
+, S-S 60 mg
Tyr replicate 2 TyrRS/tRNACUA 17021.6943 17041.6996 20.005 +Na
+, S-S 120 mg
Tyr AzRS3/3SUP-tRNACUA 17021.6943 17042.7675 21.073 +Na
+, S-S 42 mg
AmF replicate 1 AzRS3/3SUP-tRNACUA 17020.7096 17043.7254 23.016 +Na
+ 78 mg
AmF replicate 2 AzRS3/3SUP-tRNACUA 17020.7096 17042.3620 21.652 +Na
+, S-S 114 mg
AmF replicate 3 AzRS3/3SUP-tRNACUA 17020.7096 17043.0344 22.325 +Na
+ 90 mg
PxF PxRS1/3SUP-tRNACUA 17059.7424 17057.7976 21.945 S-S 96 mg
Bpa BpaRS/tRNACUA 17109.8012 17108.9558 20.845 80 mg
Only variant proteins for which defined mass spectra were obtained are shown. The same hSOD1 variants were detected on the immunoblot in Figure 2. The
corresponding ESI-MS spectra are shown in Figure 3. All hSOD1 variants were found with the N-terminal methionine cleaved off and acetylated alanine at position 2, as
reported in the literature [41]. The occasionally attached sodium ions (+22.99 Da) most probably originated from the Strep-Tactin elution buffer which contained
150 mM NaCl. The buffer was not exchanged during sample concentration in order to avoid protein loss. In some of the protein preparations we found a known
disulfide bond (S-S, 22 Da; between C57 and C146 [70]).
1All hSOD1 masses were calculated without N-terminal methionine, acetylated alanine at position 2 and with completely reduced cysteines.
doi:10.1371/journal.pone.0031992.t002
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the tandem vector for optimized tRNACUA expression (Table 1;
[29]) while the originally described vector containing only one
copy of the gene and no optimized promoter (Table 1; [18]) was
inefficient. This confirms the published observation [29] that three
copies of tRNACUA and the optimized promoter result in
improved amber stop suppression.
Surprisingly, we obtained a rather strong immunoblot signal
upon expression of hSOD1(W33TAG) in the presence of AmF
and the AzRS3/3SUP-tRNACUA o-pair optimized for AzF
(Figure 2B, lanes 4–5). Our attempts, however, to confirm
incorporation of AmF by mass analysis were inconclusive owing
to a calculated mass difference of only 1 Da between AmF and
Tyr. The ESI-MS produced strong signals but the resolution was
too low to unambiguously distinguish between intact hSOD1(-
W33AmF) and hSOD1(W33Y) (see Table 2 for calculated and
found masses; Figure 3D–F). Direct LC-MS/MS analysis of the
trypsin-digested protein preparation was disappointing (data not
shown), as we could not identify the specific peptide fragment
carrying the ncAA. Yet, there is indirect evidence that we isolated
an hSOD1(W33AmF) variant. The concentrations of Tyr and the
other canonical amino acids in the expression medium were too
low to support amber suppression with the AzRS3/3SUP-
Figure 4. Activation of Tyr, AzF, and AmF by TyrRS and the AzRSs. Tyr, AzF and AmF were used at a concentration of 5 mM. No amino acid
was added to the negative control (w/o aa). TyrRS (A) was added at 1 mM and AzRS1 (B), AzRS3 (C), and AzRS6 (D) at a concentration of 5 mM. The
data for each o-aaRS were collected in one series of experiments (see Materials and Methods for details). The average of duplicate determinations is
shown; the bars indicate the discrete values.
doi:10.1371/journal.pone.0031992.g004
Figure 5. Activation of Tyr, Bpa, AzF, and AmF by BpaRS. Tyr,
Bpa, AzF and AmF were used at a concentration of 5 mM. In the
negative control, the amino acid was omitted (w/o aa). BpaRS was
added at a concentration of 3 mM. The data were all recorded in one
row of experiments and each value was determined in duplicate. The
bars denote the discrete values.
doi:10.1371/journal.pone.0031992.g005
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incorporation experiments with AzF. These observations strongly
argue against the incorporation of Tyr or any other canonical
amino acid in the presence of AmF.
Our finding indicates a hitherto unrecognized specificity of
AzRS3 for AmF. Indeed, o-aaRSs with extended substrate
tolerance have recently been described [52,53]. These o-aaRSs
accept various ncAAs (up to 18 different species [53]) as their
substrates yet they retain their ability to discriminate against the 20
canonical amino acids. The tolerance of AzRS3 for AmF might
occur coincidentally as described for other o-aaRSs. It may,
however, have been nurtured by the chemical properties of AzF.
AmF is a reduced derivative of AzF. It was observed after
incorporation of AzF into different target proteins produced in
various host systems (E. coli [54,55], S. cerevisiae [18,19,29,42], and
mammalian cells [21]), using different purification methods (Ni-
chelate chromatography [18,19,29,42,54,55] vs. affinity chroma-
tography [21]), or different mass analysis techniques (ESI-TOF
[54], LC-MS/MS [18,19,21,42], or multiple-reaction monitoring
[29]). These observations were accredited to ‘‘the chemical
reactivity and photoinstability of the azido group’’ [21] or
interpreted as artifacts generated during mass analysis [18,54].
e.g., by the reducing conditions used for in-gel digestion of
proteins. Mass spectrometry of full length proteins does not
necessarily require reducing conditions. Accordingly, Chin et al.
did not detect decomposition of AzF to AmF by mass spectrometry
of intact AzF-labeled sperm whale myoglobin isolated from E. coli
[55]. Moreover, they purified their protein ‘‘under a red
photographic light, to avoid photolysis of the aryl-azide’’ [55]. In
contrast, Wan et al observed noticeable amounts of AmF in their
protein preparations by ESI-TOF analysis. Most probably this was
due to the reducing buffer with 10 mM DTT in which they had
lysed the E. coli cells [54]. Whether decomposition of AzF to AmF
already occurs in the cellular environment or is an artifact
generated by the conditions during mass analysis, or both, has not
yet been unequivocally resolved. This issue is important with
respect to bioorthogonal conjugations for which the azido group is
indispensable.
AmF insertion in place of AzF in yeast might originate from the
direct incorporation of AmF by a dual specificity of the o-aaRS.
Arylazides such as AzF can be biocatalytically reduced to the
amines by yeast [33,34]. The (partial) conversion of AzF into AmF
already during the selection process of the o-aaRS could possibly
lead to the selection of an enzyme with dual substrate specificity.
In our experiments, AzRS3 behaved more like an AmF-specific o-
aaRS since we observed full length hSOD1 only upon amber
suppression with AmF and not with AzF (Figure 2B, lanes 4–6 vs.
lane 2).
As already mentioned above, the Schultz group was able to
incorporate AzF into a hSOD1(33TAG) mutant and demonstrat-
ed the bioorthogonal conjugation of the azido-functionalized
protein with two different alkyne-fluorophors [19] and alkyne-
PEG [42]. However, from these reports it cannot be deduced
whether the AmF variant was also present in their protein
preparation. They exclusively found AmF containing tryptic
fragments in their LC-MS/MS analysis, most probably again
due to the reducing conditions during in-gel digestion. However,
they did not discuss this issue. They also performed a MALDI-
TOF analysis of the intact PEGylated protein but the mass range
in the presented spectrum is cut off at approximately 18500 Da
[42] and, therefore, does not extend to the lower masses of the
unconjugated AzF or AmF variants (calculated masses:
16671.2560 Da and 16645.2584 Da, respectively; the calculation
was based on the hSOD1 sequence published by Tippmann et al.
[40] and N-terminal methionine excision and acetylation of the
alanine residue in the second position were taken into account; the
calculated mass difference between the N-terminally modified and
the unmodified proteins is 89 Da).
The unsatisfactory incorporation of AzF and PxF in our study
might originate from inefficient expression in yeast of their
respective charging enzymes, AzRS, and PxRS. Previous reports
largely neglected this issue. Chen et. al analyzed the mRNA levels
of a PxF-specific o-aaRS, however, they did not analyze the
protein expression [29]. The intracellular expression of AzRS1
from our reconstructed tandem vector (Figure S1 and Methods S1)
was clearly detectable by immunoblotting while we observed no or
only low expression of AzRS3 (from pAz3/3SUP-tRNACUA) and
PxRS1 (from pPR1/3SUP-tRNACUA), respectively (Figure S5).
Since AzF was neither incorporated in the presence of AzRS1 nor
of AzRS3, the intracellular availability of the charging enzyme
does not appear to be the primary reason for the incorporation
failure. The PxRS1 levels, however, could have been too low for
efficient activation and charging of PxF. In order to obtain a
comprehensive overview of o-pair functionality, it would be
necessary to analyze not only the intracellular levels of the o-aaRSs
but also those of the empty vs. charged tRNACUA.
In order to strengthen our performance analysis of yeast o-pairs
we not only conducted in vivo incorporation experiments with
different ncAAs but also validated these findings against catalytic
data collected in vitro. For the characterization of the catalytic
properties of TyrRS, AzRS1, AzRS3, AzRS6, and BpaRS, we
purified the enzymes from E. coli and analyzed their ability to
activate different ncAA substrates in vitro. We could not include
PxRS1 in this study since our PxF preparation contained residual
Tyr as detected by mass analysis (Figure S10), which would have
obscured the results of the activation assays. Unfortunately, PxF is
not commercially available.
As expected, TyrRS activated only Tyr and neither AzF, nor
AmF (Figure 4A). The purified o-aaRSs, however, did not activate
AzF, AmF nor Bpa, while Tyr was activated by all of them
(Figure 4B–D and Figure 5). Due to the fact that the activation
readout was close to background at all tested analog concentra-
tions (Figure 4B–D, Figure 5 and Figure S9), even when they were
used at 5 mM, we were unable to assess the Michaelis constant
KM ncAA of the different enzymes. Our findings cannot be
attributed to an inadequate experimental setup since under the
same conditions the previously described E. coli Gly294PheRS
mutant enzyme [56,57,58,59] activated a whole set of Tyr, Phe,
and Trp analogs as shown in Figure S11.
Contrary to our expectations, we found that all o-aaRSs
activated preferentially Tyr (Figure 4B–D, Figure 5, and Figure
S9). However, Tyr was rather inefficiently incorporated into
hSOD1(W33TAG) in vivo by the pAz3/3SUP-tRNACUA o-pair
only if the medium was supplemented with excess Tyr (Figure 2B,
lane 3). Unfortunately, the Schultz group did not report the kinetic
parameters of the o-aaRSs derived from E. coli TyrRS for the
incorporation of AzF or Bpa in yeast. Thus, we can only speculate
why an amino acid that is clearly activated by the o-aaRSs only
appears in the target protein if it is supplied in excess in the
medium (Figure 2B, lane 3). In a prototrophic yeast strain growing
in minimal medium without tyrosine, the intracellular Tyr
concentration varies between 0.2 mM and 3 mM during the
different growth phases [60]. Our SC –Ura –Trp medium for
incorporation of tyrosine analogs contained 0.3 mM Tyr, and
InvSC1 is prototrophic for the amino acid (see Materials and
Methods for details). Unless Tyr is excluded from the cells, we
suppose its intracellular concentration to rank in a comparable
sub-millimolar range. The results in Figure S9 clearly show that
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the different AzRSs while the different ncAAs showed activation
close to background at all tested concentrations (Figure 4, Figure 5,
and Figure S9). Thus, from our results we would expect
preferential activation of Tyr already at the normal concentration
in the SC –Ura –Trp medium even in the presence of excess
ncAA.
It might be possible that Tyr is not or only inefficiently charged
onto the tRNACUA although it is efficiently activated by an o-
aaRS. However, charging of tRNACUA with Tyr or the ncAAs by
an o-aaRS, such as AzRS, PxRS, or BpaRS, has not been
systematically analyzed so far. Most probably, this owes to the fact
that only a couple of radiolabeled ncAAs, that are required for the
classical aminoacylation assay, are commercially available. An
alternative aminoacylation assay that involves radioactive tRNA
rather than labeled amino acids has recently been described [44]
and could be used for a future, more detailed analysis of the
aminoacylation reaction of tRNACUA with ncAAs by the o-aaRSs.
Most strikingly, Bpa was incorporated into hSOD1 (Figure 2C)
although the analog was not activated by BpaRS in vitro (Figure 5)
when used at 5 mM. Due to the low solubility of Bpa in aqueous
solution it was not possible to use higher concentrations in the
activation assay. It is generally accepted that an amino acid must
be activated before it can be charged onto a tRNA [2,61]. In vivo
activation and subsequent charging onto suppressor tRNACUA by
an unspecific BpaRS can plausibly occur if Bpa is efficiently taken
up into the cells and accumulates intracellularly to levels above
5 mM. This is possible if the substance is actively imported into
the cells and piles up because it is not metabolized. Indeed, Wang
and co-workers observed roughly 9 mM intracellular dansylala-
nine upon esterification of the amino acid [62]. Giese et al. recently
demonstrated that fluorinated tryptophan is actively taken up into
mammalian cells to an intracellular concentration exceeding the
extracelluar by 70-fold [63]. A comparable accumulation could
elevate the intracellular Bpa concentration above 5 mM when the
cells are supplemented with 1 mM in the medium, as in our
experiments. The assessment of the intracellular Bpa concentra-
tion would help to clarify this issue. In any case, the intracellular
availability of the non-canonical amino acid is an important factor
that governs the specificity of the o-aaRS and, thus, the fidelity of
the incorporation [29].
In numerous studies, the site-specific incorporation of ncAAs
into target proteins in response to amber codons was shown to
occur with high fidelity and without significant amounts of
canonical amino acids at the designated positions. However,
reports on the catalytic properties of the evolved o-aaRSs as well as
the intracellular availability and fate of the amino acid analogs are
still rare exceptions [16,17,62]. If the modification of proteins by
ncAAs is to extend beyond the proof-of-principle level, thorough
characterization of the incorporation systems is urgently required.
Polysubstrate specificity, i.e. broad substrate tolerance of aaRSs
appears to be a general phenomenon. Naturally occurring
enzymes usually show it, and this trait can be exploited for the
global incorporation of amino acid analogs into proteins [64]. O-
aaRSs evolved to recognize a specific ncAA can also tolerate
alternative substrates [52,53]. This property could ease a broader
applicability of the already existing o-pairs. However, natural
enzymes and their cognate tRNAs are superior to the currently
available orthogonal aaRS/tRNACUA pairs in terms of efficiency.
In our opinion, the future strategies for the improvement of the o-
pairs will enormously profit from the thorough characterization of
the overall analog incorporation process. This involves the uptake
of the ncAA into the cells, its cellular availability, the activation,
and charging onto tRNACUA and finally the sequence context for
the incorporation at the position of the amber stop codon
[29,65,66]. The results of this thorough analysis will aid the design
of o-pairs that can stand the comparison with the naturally
occurring systems.
Materials and Methods
Materials
Unless otherwise indicated all chemicals were from Fluka (Neu-
Ulm, Germany) or Merck (Darmstadt, Germany). Restriction
endonucleases and T4 ligase were from New England Biolabs
(Beverly, MA). ExTaq and rTaq DNA polymerases for proof-
reading and standard PCR reactions, respectively, were from
TaKaRa Bio Inc. (Saint-Germain-en-Laye, France), PfuUltra II
HS-DNA-Polymerase for site-directed mutagenesis PCR was from
Stratagene (La Jolla, CA).
Construction of the tandem expression vectors for
orthogonal pairs
The reconstruction of the expression vectors pTyr/tRNACUA,
pAz1/tRNACUA and pAz6/tRNACUA (Figure S1) were performed
as described previously [18,19,27,28]. Primers tRNA(CUA)tem-
plate_fwd and tRNA(CUA)template_rev, containing the coding
sequence for the E. coli tRNACUA gene, were annealed and the
resulting double strand DNA was used for PCR amplification with
primers tRNA59 (contains an AgeI cleavage site) and tRNA39
(contains an NheI site, see Table S2 for primer sequences). The
PCR product and the pESCTrp (Stratagene) target vector were
both digested with NheI and AgeI and ligated, which yielded
ptRNACUA. The ADH1-promoter for the expression of the E. coli
TyrRS in S. cerevisiae was generated by PCR using the primers
pADHf (AgeI site) and pADHr (EcoRI site) together with genomic
S. cerevisiae DNA as the template. The PCR product was digested
with EcoRI and AgeI. The E. coli TyrRS gene was PCR-amplified
with the primers pESCTrp1 (EcoRI site) and pESCTrp2 (NotI site)
and genomic E. coli DNA as the template. Afterwards the PCR
product was digested with EcoRI and NotI. The pTyr/tRNACUA
tandem vector was obtained by ligating AgeI/NotI digested
ptRNACUA with the AgeI/EcoRI digested ADH1-promoter and E.
coli TyrRS cut with EcoRI and NotI. The pAz1/tRNACUA
descendant encoding the TyrRS mutant AzRS1 was generated
by site directed mutagenesis PCR using the pTyr/tRNACUA
vector as the template. The primer pair 59-/39Muta_N126N was
used to introduce the silent mutation N126N. The additional
mutations were introduced using the primer pairs 59tyr_-
muta3306-1/pESCTrp2, 59tyr_muta3306-2/pESCTrp2, and
59tyr_muta3306-3/pESCTrp2. Each resulting mutant plasmid
was used as the template for the subsequent mutagenesis PCR.
AzRS6 was generated by introducing additional mutations into
AzRS1 using mutagenesis primer pairs Thr37f/Thr37r, Ala183f/
Ala183r, and Leu186f/Leu186r. Figure S2 shows the mutations
that were introduced into TyrRS to generate the o-aaRSs.
Mutagenesis primers are listed in Table S2. All vectors were
verified by sequencing.
Construction of the hSOD1(W33TAG) expression vector
The gene for the human superoxide dismutase (hSOD1) was
PCR-amplified from the cDNA vector pOTB7 (ATCC number
MGC-2325; LGC Promochem GmbH, Wesel, Germany) with the
primers hSODfp (HindIII site) and hSODrp (EcoRI site). A
hexahistidine-tag was introduced at the C-terminus of hSOD1 by
primer hSODrp (see Table S2 for primer sequences). The PCR
product and the high copy yeast-E. coli shuttle vector pYES2
(Invitrogen, Carlsbad, CA) were both digested with HindIII and
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codon at position 33 of hSOD1 was mutated to an amber stop
codon ATG by site directed mutagenesis PCR with the primers
SODmutf and SODmutr (Table S2). Furthermore, the inducible
GAL promoter on pYES2-hSOD1(W33TAG)-6His was exchanged
for the stronger constitutive PGK1 promoter via homologous
recombination in yeast. To achieve this, the GAL promoter was
excised from pYES2-hSOD1(W33TAG)-6His with SpeI and PvuII.
The DNA sequence of the PGK1 promoter was amplified by PCR
with primers PGK1fp and PGK1rp (Table S2) using genomic S.
cerevisiae DNA as the template. In order to facilitate efficient
homologous recombination, the primers PGK1fp and PGK1rp
introduced flanking sequences of 43 nt and 35 nt, respectively to
the PGK1 promoter sequence. These sequences were homologous
to the ends of the cut pYES2 vector. The PGK1 PCR product with
the flanking homology regions and the SpeI/PvuII digested pYES2-
hSOD1(W33TAG)-6His were co-transformed into S. cerevisiae
strain InvSc1 (MATa/a his3D1/his3D1 leu2/leu2 trp1-289/
trp1-289 ura3-52/ura3-52; Invitrogen) by the lithium acetate
method [67] and clones carrying successfully recombined
plasmids, which were designated pYES2-hSOD1(W33TAG)-
6His, were selected on synthetic complete medium lacking uracil
(SC –Ura; 1% glucose, 0.67% yeast nitrogen base (Difco
Laboratories, MI), 1.92 g/L yeast synthetic drop-out medium
supplement without uracil (Sigma, Deisenhofen, Germany)).
In a similar way, we exchanged the hexahistidine-tag for the
Strep-tag II. The pYES2-hSOD1(W33TAG)-6His vector was
linearized with EcoRI and the Strep-tag II coding sequence with
appropriate homology hooks was amplified by PCR with primers
hSOD1_Strep_fp and hSOD1_Strep_rp (see Table S2). Homol-
ogous recombination and screening of positive clones containing
pYES2-hSOD1(W33TAG)-Strep was as described above for the
promoter exchange.
Expression and purification of hSOD1(W33TAG) variants
containing Tyr analogs
The S. cerevisiae expression strain InvSc1 was co-transformed
with one of the o-pair expression vectors and pYES2-
hSOD1(W33TAG)-Strep by the lithium acetate method [67].
Positive transformants were selected on synthetic complete
medium lacking uracil and tryptophan, but containing all other
amino acids (SC –Ura –Trp; 1% glucose, 0.67% yeast nitrogen
base (Difco), 1.4 g/L yeast synthetic drop-out medium supplement
without histidine, leucine, tryptophan and uracil (Sigma), 76 mg/
L histidine (Sigma), 380 mg/L leucine (Sigma); the medium
contains 76 mg/L or 0.3 mM tyrosine disodium salt). For
incorporation experiments, 5 mL SC –Ura –Trp medium were
inoculated with the transformed expression strain and this starter
culture was grown with vigorous shaking at 30uC over night.
Subsequently, 50 mL SC –Ura –Trp were inoculated to an OD600
of 0.2 with the starter culture and incubated with shaking at 30uC
for 24 h. Finally, we inoculated 500 mL SC –Ura –Trp medium
supplemented with 1 mM of Tyr or one of the analogs with the
pre-culture to an OD600 of 0.2. The amino acid was directly
dissolved in the expression medium, which was then filter sterilized
before inoculation. The hSOD1 variants were expressed with
vigorous shaking at room temperature for 48 h. Cells were
harvested by low speed centrifugation (30006g, room tempera-
ture, 5 min) and the cell pellets were stored at 280uC until protein
preparation.
To purify the hSOD1 variants, we lysed the yeast cells with Y-
PER (Pierce, Rockford, IL) following the manufacturer’s instruc-
tions. The lysate was cleared by centrifugation (140006g, room
temperature, 10 min) and applied onto a Strep-Tactin-column
(1 mL column volume (CV); IBA BioTAGnology, Gottingen,
Germany). After protein binding, the column was washed with 5
CVs of washing buffer (100 mM Tris/Cl pH 8.0, 150 mM NaCl,
1 mM EDTA). Bound protein was eluated 6 times with 0.5 CVs of
elution buffer (100 mM Tris/Cl pH 8.0, 150 mM NaCl, 1 mM
EDTA, 1 mM desthiobiotin) each. Eluates were pooled and
concentrated to a total volume of 150 ml by ultrafiltration
(Centricon YM-10, MWCO 10,000; Amicon, Beverly, MA).
Immunoblotting
Of each concentrated hSOD1 variant, 20 ml were run on a 12%
Laemmli gel [68]. After electrophoresis, the proteins were blotted
onto nitrocellulose membrane (Schleicher and Schuell GmbH,
Dassel, Germany) for immunodetection [69]. The membranes
were blocked with TTBS (50 mM Tris/Cl, pH 8.0, 150 mM
NaCl, 0.1% (v/v) Tween20) containing 1.5% (w/v) bovine serum
albumin (SERVA Electrophoresis GmbH, Heidelberg, Germany)
and probed with monoclonal mouse anti-Strep-tag II antibody
MAB-Class (IBA BioTAGnology) as the first and horseradish
peroxidase conjugated goat anti-mouse IgG (IBA BioTAGnology)
as the second antibody. Tagged proteins were visualized by
chemiluminescence detection (Pierce, Rockford, IL).
Electro spray ionization mass spectrometry (ESI-MS)
For ESI-MS, 20 ml aliquots of the purified hSOD1 variants or
the o-aaRSs were pre-separated on a Waters RP C4 column (300
A ˚ pore size; 3.5 mm particle size; 10062.1 mm; Waters GmbH,
Eschborn, Germany) by eluting with a gradient from 20 to 90% B
in A within 20 min, where eluent A was 0.05% (v/v) TFA in water
and eluent B was 0.05% (v/v) TFA in acetonitrile. A flow rate of
250 ml/min was used. The masses of the eluted fractions were
analyzed on a MicroTOF ESI-MS (Bruker Daltonics, Bremen,
Germany).
Cloning and expression of wild type TyrRS and the o-
aaRSs for the ATP-PPi exchange assay
Cloning. The sequences encoding wild type TyrRS and the
o-aaRSs were PCR amplified with primers pESCTrp1 and
pESCTrp2 (Table S2) from corresponding o-pair expression
vectors as templates. The primers contain an EcoRIo rNotI
cleavage site, respectively, flanked by additional nucleotides at
their 59-ends for efficient restriction. The PCR fragments were
digested with EcoRI and NotI (New England Biolabs) and inserted
into pET28a (Merck KGaA, Darmstadt, Germany) cleaved with
the same enzymes, so that the hexahistidine-tag of the pET28a
vector was attached to the N-terminus of the aaRSs. The resulting
expression plasmids pET28a-H6-aaRS were sequence-verified.
Protein expression. The pET28a-H6-aaRS expression
vectors were introduced into the E. coli strain B834 (DE3) (F
2
ompT hsdSB(rB
2 mB
2) gal dcm met (DE3); Novagen Merck
Chemicals, Nottingham, UK) by electroporation following
standard laboratory procedures. Plasmid-harboring clones were
selected and propagated in media containing 50 mg/L
kanamycin. The sequences of the expression plasmids were
verified by sequencing. For aaRS expression, the cells were
grown in 1 liter LB (Luria Broth) medium at 37uC until they
reached mid-log phase (OD600 0.6–0.8). Then, gene expression
was induced by the addition of 1 mM isopropyl-b-D-1-
thiogalactopyranoside (IPTG; Applichem, Darmstadt, Germany)
and was performed for 4–5 h at 25uC with vigorous shaking.
Protein purification. The cells were harvested by low speed
centrifugation (3,2006 g, 4uC, 20 min) and the cell pellet was
resuspended in sodium phosphate buffer (50 mM NaH2PO4,
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1 mg/mL DNase (Roche, Mannheim, Germany), RNase (Sigma),
and lysozyme (Sigma) each, cells were ruptured by sonication and
the homogenate cleared from cell debris by high speed
centrifugation (30,0006 g, 4uC, 30 min). The clear lysate was
loaded onto a 5 mL HiTrap Chelating HP column (GE
Healthcare, Munich, Germany), which was then washed with 10
CVs of sodium phosphate buffer containing 20 mM imidazole.
Bound proteins were eluted by applying an imidazole gradient
(20–250 mM) in sodium phosphate buffer. The elution fractions
were analyzed by SDS-PAGE and those enriched in the desired
aaRS were pooled and first dialyzed against 20 mM Tris?HCl
pH 8.0 and then against aaRS-buffer (20 mM Tris/Cl pH 8.0,
150 mM KCl, 15 mM MgCl2 and 5 mM b-mercaptoethanol).
The dialyzed fractions were concentrated by ultrafiltration
(Vivaspin 20 MWCO 10,000; Sartorius AG, Go ¨ttingen,
Germany). Finally, the concentration of the protein samples was
determined by recording the absorption at 280 nm and purity was
analyzed by SDS-Page (Figure S6) and ESI-MS mass analysis
(Figure S7).
ATP-PPi exchange assay. The reaction mix contained
100 mM Tris/Cl pH 8.0, 80 mM MgCl2, 5 mM KF, 700 mM
b-mercaptoethanol, 5.5 mM ATP, 0.1 mg/mL BSA, 2.2 mM
[
32P]-PPi (0.2 cpm/pmol; PerkinElmer, Rodgau, Germany), 5 mM
of the o-aaRS (or 1 mM of wild type TyrRS), and 5 mM (or less, as
indicated) of Tyr or Tyr analogs in a final volume of 200 ml. For
the assay, 20 mM stock solutions of the purified aaRSs in aaRS-
buffer were used. All amino acids were dissolved in 0.01 M HCl at
a concentration of 12.5 mM and 80 ml of these amino acid
solutions were used in each reaction mix (200 ml) to obtain 5 mM
of amino acid final concentration. Lower amino acid
concentrations were prepared by dilution in 0.01 M HCl, and
0.01 M HCl was used as the negative control (w/o aa). Each value
was determined twice. After 15 min at 37uC, the reaction was
quenched by mixing 100 ml of the reaction mix with 600 mlo f
240 mM sodium pyrophosphate solution containing 70% (v/v)
perchloric acid. [
32P]-ATP formation was followed by specific
absorption to 200 ml of 7.5% (w/v) activated charcoal. The
suspension was thoroughly mixed and filtered through Whatman
GF/F paper (Whatman International Ltd, Maidstone Kent, UK).
Filters were washed twice with 10 mL of water before immersion
in scintillation solution (Rotiszint eco plus; Carl Roth GmbH Co.,
Karlsruhe, Germany) to determine the amount of adsorbed
radioactivity.
Supporting Information
Figure S1 Plasmid map of the tandem expression vector
for the orthogonal aaRS/tRNACUA pairs. The aaRS is
expressed under the strong, constitutive ADH1 promoter on a
yeast/E. coli shuttle vector containing an ampicillin resistance gene
(AmpR) and the ColE1 origin of replication for selection and
propagation in E. coli, respectively. The TRP1 auxotrophy marker
and the 2m origin of replication ensure plasmid maintenance in
yeast. The amber suppressor tRNA (tRNACUA) expression
cassettes are detailed in Table 1. The following tandem expression
vectors were used in this work (the original o-aaRS nomenclature
is given in brackets): pTyr/tRNACUA for TyrRS (TyrRS [18]),
pAz1/tRNACUA for AzRS1 (p-azidoPheRS1 [18]), pAz3/3SUP-
tRNACUA for AzRS3 (p-azidoPheRS3 [29]), pAz6/tRNACUA for
AzRS6 (p-azidoPheRS6 [18]), pPR1/3SUP-tRNACUA for PxRS1
(p-PpaRS1 [29]) and pBpa/tRNACUA for BpaRS (p-benzoyl-
PheRS2 [18]).
(TIF)
Figure S2 DNA and protein sequence alignment of
TyrRS and the o-aaRSs. Mutated bases and exchanged amino
acid residues are highlighted in color.
(TIF)
Figure S3 The hSOD1(W33TAG) expression vector.
Constitutive expression of hSOD1 with an in-frame amber stop
codon (TAG) in position 33 and a C-terminal Strep-tag II is driven
by the constitutive PGK1 promoter. The yeast/E. coli shuttle vector
contains an ampicillin resistance gene (AmpR) and the ColE1 origin
of replication for selection and propagation in E. coli, respectively.
The URA3 auxotrophy marker and the 2m origin of replication
ensure plasmid maintenance in yeast.
(TIF)
Figure S4 DNA and protein sequence of the
hSOD1(W33TAG) open reading frame with a C-terminal
Strep-tag II. The position of the amber stop codon (bold boxed)
is indicated as X (bold black) in the protein sequence, hSOD1 is
highlighted in green and the Strep-tag II in orange.
(TIF)
Figure S5 Intracellular expression of the o-aaRSs from
different orthogonal pairs. Sample preparation and immu-
nodetection are described in Methods S1. For immunodetection, a
C-terminal hexahistidine-tag was added to AzRS1 on pAz1/
tRNACUA by homologous recombination as described in Methods
S1. AzRS3 and PxRS1 on pAz3/3SUP-tRNACUA and pPR1/
3SUP-tRNACUA, respectively, originally contained a C-terminal
hexahistidine-tag [29]. While only a single clone was analyzed for
AzRS1(His) expression (lane 1), three different clones each were
analyzed for expression of AzRS3 (lanes 2–4), and PxRS1 (lanes
5–7). The calculated molecular weight of the o-aaRSs is 48 kDa.
M, molecular weight marker; +, wild type hSOD1 with a C-
terminal hexahistidine-tag (positive control); -, empty lane.
(TIF)
Figure S6 Purified E. coli wild type TyrRS and o-aaRSs.
aaRSs were expressed in E. coli and purified by Ni-NTA affinity
chromatography. The proteins were concentrated by ultrafiltra-
tion and analyzed by SDS-PAGE. The calculated molecular
weight of TyrRS and the o-aaRSs is 51 kDa. 1, TyrRS; 2, AzRS1;
3, AzRS6; 4, AzRS3; 5, BpaRS; M, molecular weight marker. The
gel was cut between lanes 4 and 5 to remove irrelevant lanes.
(TIF)
Figure S7 ESI-MS analysis of E. coli wild type TyrRS
and the o-aaRSs shown in Figure S6 and Table S1. TyrRS
(A); AzRS1 (B); AzRS3 (C); AzRS6 (D); BpaRS (E).
(TIF)
Figure S8 ATP-PPi exchange assay of TyrRS with
different concentrations of Tyr. Different concentrations of
Tyr were used to determine the substrate range for non-saturated
enzyme activity (A) and for substrate saturation (B). In the negative
control, no amino acid was added to the reaction mix (w/o aa).
TyrRS was used at a concentration of 1 mM. The data in (A) and
(B) were collected in one series of experiments each and the ATP
formation with each tyrosin concentration was determined in
duplicate. Mean values are shown; the bars denote the discrete
values.
(TIF)
Figure S9 Activation of Tyr, AzF and AmF at low
concentrations by the different AzRSs. In order to exclude
effects of substrate inhibition in the ATP-PPi assay, 5 mM each of
AzRS1 (A), AzRS3 (B), and AzRS6 (C) were incubated with Tyr,
AzF, and AmF at concentrations that had caused linear activation
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amino acid was added to the reaction mix (w/o aa). The data for
each aaRS were all collected in one series of experiments. Mean
values of duplicates are shown; the bars denote the discrete values.
(TIF)
Figure S10 ESI mass spectrum of the PxF preparation.
Among other unidentified impurities, approximately 1% Tyr
(corresponding mass indicated in red in the lower panel) was
present, most probably originating from the chemical synthesis
[19]. The lower panel shows the same mass spectrum as the upper
panel albeit at a magnified intensity scale (610
6 in the upper vs.
610
4 in the lower panel).
(TIF)
Figure S11 Activation of different amino acids and their
analogs by E. coli PheRS (Gly294Phe). The negative control
did not contain an amino acid (w/o aa). PheRS (Gly294Phe) [56]
was added at a concentration of 3 mM and the amino acid analogs
at 5 mM. Besides the amino acids shown in Figure 1, the following
ncAAs were used: MY (O-methyl-L-tyrosine), IF (p-iodo-L-
phenylalanine), FA (L-(2-furyl)-alanine), AA (azulenyl-L-alanine),
6ClW (6-chloro-DL-tryptophan), 5BrW (5-bromo-DL-trypto-
phan), BT (benzothienyl-L-alanine), Nal (naphthyl-L-alanine).
The data were all collected in one series of experiments. Mean
values of duplicates are shown; the bars denote the discrete values.
(TIF)
Table S1 Mass analysis of E. coli wild type TyrRS and
the different o-aaRSs.
(DOC)
Table S2 DNA primer sequences.
(DOC)
Methods S1 Contains the technical details for the
analysis of the intracellular expression of the TyrRS
mutants.
(DOC)
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